GB9514451D0 - Sustained-release formulation - Google Patents

Sustained-release formulation

Info

Publication number
GB9514451D0
GB9514451D0 GBGB9514451.5A GB9514451A GB9514451D0 GB 9514451 D0 GB9514451 D0 GB 9514451D0 GB 9514451 A GB9514451 A GB 9514451A GB 9514451 D0 GB9514451 D0 GB 9514451D0
Authority
GB
United Kingdom
Prior art keywords
sustained
release formulation
threo
methylphenidate
subject invention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9514451.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chirotech Technology Ltd
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Priority to GBGB9514451.5A priority Critical patent/GB9514451D0/en
Publication of GB9514451D0 publication Critical patent/GB9514451D0/en
Priority to US08/679,875 priority patent/US5874090A/en
Priority to CZ9892A priority patent/CZ285956B6/cs
Priority to SK29-98A priority patent/SK281569B6/sk
Priority to PCT/GB1996/001690 priority patent/WO1997003673A1/en
Priority to AT96924083T priority patent/ATE224715T1/de
Priority to JP9506412A priority patent/JPH11509228A/ja
Priority to HU9802252A priority patent/HU224314B1/hu
Priority to DE69623970T priority patent/DE69623970T2/de
Priority to KR10-1998-0700286A priority patent/KR100481416B1/ko
Priority to ES96924083T priority patent/ES2186790T3/es
Priority to CA002223643A priority patent/CA2223643C/en
Priority to DK96924083T priority patent/DK0841928T3/da
Priority to EP96924083A priority patent/EP0841928B1/en
Priority to PT96924083T priority patent/PT841928E/pt
Priority to AU64661/96A priority patent/AU702371B2/en
Priority to MX9800394A priority patent/MX9800394A/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
GBGB9514451.5A 1995-07-14 1995-07-14 Sustained-release formulation Pending GB9514451D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB9514451.5A GB9514451D0 (en) 1995-07-14 1995-07-14 Sustained-release formulation
AU64661/96A AU702371B2 (en) 1995-07-14 1996-07-15 Sustained-release formulation of D-threo-methylphenidate
DE69623970T DE69623970T2 (de) 1995-07-14 1996-07-15 Formulierung von d-threo methylphenidat mit verzögerter freisetzung
ES96924083T ES2186790T3 (es) 1995-07-14 1996-07-15 Formulacion de d-treo-metilfenidato de liberacion prolongada.
SK29-98A SK281569B6 (sk) 1995-07-14 1996-07-15 Prípravok s predĺženým uvoľňovaním obsahujúci metylfenidát
PCT/GB1996/001690 WO1997003673A1 (en) 1995-07-14 1996-07-15 Sustained-release formulation of d-threo-methylphenidate
AT96924083T ATE224715T1 (de) 1995-07-14 1996-07-15 Formulierung von d-threo methylphenidat mit verzögerter freisetzung
JP9506412A JPH11509228A (ja) 1995-07-14 1996-07-15 Ｄ−トレオ−メチルフェニデートの持効性剤型
HU9802252A HU224314B1 (hu) 1995-07-14 1996-07-15 D-treo-metil-fenidátot tartalmazó, késleltetett hatóanyag-felszabadítású készítmény
US08/679,875 US5874090A (en) 1995-07-14 1996-07-15 Sustained-release formulation of methylphenidate
KR10-1998-0700286A KR100481416B1 (ko) 1995-07-14 1996-07-15 디-트레오-메틸페니데이트의지속적인방출제형물
CZ9892A CZ285956B6 (cs) 1995-07-14 1996-07-15 Prostředek trvale uvolňující D-treomethylfenidát
CA002223643A CA2223643C (en) 1995-07-14 1996-07-15 Sustained-release formulation of d-threo-methylphenidate
DK96924083T DK0841928T3 (da) 1995-07-14 1996-07-15 Sustained release-formulering af d-threo-methylphenidat
EP96924083A EP0841928B1 (en) 1995-07-14 1996-07-15 Sustained-release formulation of d-threo-methylphenidate
PT96924083T PT841928E (pt) 1995-07-14 1996-07-15 Formulacao de libertacao prolongada de d-trep-metilfenidato
MX9800394A MX9800394A (es) 1995-07-14 1998-01-13 Formulacion de liberacion sostenida de d-treo-metilfenidato.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9514451.5A GB9514451D0 (en) 1995-07-14 1995-07-14 Sustained-release formulation

Publications (1)

Publication Number Publication Date
GB9514451D0 true GB9514451D0 (en) 1995-09-13

Family

ID=10777685

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9514451.5A Pending GB9514451D0 (en) 1995-07-14 1995-07-14 Sustained-release formulation

Country Status (17)

Country Link
US (1) US5874090A (cg-RX-API-DMAC7.html)
EP (1) EP0841928B1 (cg-RX-API-DMAC7.html)
JP (1) JPH11509228A (cg-RX-API-DMAC7.html)
KR (1) KR100481416B1 (cg-RX-API-DMAC7.html)
AT (1) ATE224715T1 (cg-RX-API-DMAC7.html)
AU (1) AU702371B2 (cg-RX-API-DMAC7.html)
CA (1) CA2223643C (cg-RX-API-DMAC7.html)
CZ (1) CZ285956B6 (cg-RX-API-DMAC7.html)
DE (1) DE69623970T2 (cg-RX-API-DMAC7.html)
DK (1) DK0841928T3 (cg-RX-API-DMAC7.html)
ES (1) ES2186790T3 (cg-RX-API-DMAC7.html)
GB (1) GB9514451D0 (cg-RX-API-DMAC7.html)
HU (1) HU224314B1 (cg-RX-API-DMAC7.html)
MX (1) MX9800394A (cg-RX-API-DMAC7.html)
PT (1) PT841928E (cg-RX-API-DMAC7.html)
SK (1) SK281569B6 (cg-RX-API-DMAC7.html)
WO (1) WO1997003673A1 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
MXPA98000395A (es) 1995-07-14 2005-04-29 Medeva Europ Ltd Composicion que comprende d-treo-metilfenidato y otra droga.
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
PL205109B1 (pl) 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US7553478B2 (en) * 1999-05-12 2009-06-30 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
EP2305218A1 (en) 1999-10-29 2011-04-06 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP3856283B2 (ja) * 2000-02-14 2006-12-13 シャープ株式会社 固体撮像装置および撮像装置の駆動方法
US6221883B1 (en) * 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
DE60027282T2 (de) * 2000-06-17 2007-04-12 Pharmaquest Ltd., Hamilton Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
CN103690540A (zh) 2000-10-30 2014-04-02 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US6638533B2 (en) 2002-01-03 2003-10-28 George Krsek Pulse dosage formulations of methylphenidate and method to prepare same
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
EP1830648A4 (en) * 2004-12-09 2008-03-12 Celgene Corp TREATMENT WITH D-THREO-METHYLPHENIDATE
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
KR101495146B1 (ko) 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
WO2011020032A2 (en) * 2009-08-13 2011-02-17 Kudco Ireland, Ltd. Pharmaceutical dosage form
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP4316488A3 (en) 2011-03-23 2024-02-28 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
ES2717469T3 (es) 2012-08-15 2019-06-21 Tris Pharma Inc Comprimido masticable de metilfenidato de liberación prolongada
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
KR102174787B1 (ko) 2018-11-14 2020-11-05 호서대학교 산학협력단 재사용이 가능한 다용도 로드 및 이를 갖는 약물 투여기
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) * 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2838519A (en) * 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders

Also Published As

Publication number Publication date
KR100481416B1 (ko) 2005-07-29
ES2186790T3 (es) 2003-05-16
MX9800394A (es) 1998-09-30
DE69623970D1 (de) 2002-10-31
JPH11509228A (ja) 1999-08-17
HUP9802252A3 (en) 1999-04-28
PT841928E (pt) 2002-12-31
ATE224715T1 (de) 2002-10-15
CZ9298A3 (cs) 1998-06-17
SK2998A3 (en) 1998-07-08
CA2223643C (en) 2003-12-23
CZ285956B6 (cs) 1999-12-15
HU224314B1 (hu) 2005-07-28
WO1997003673A1 (en) 1997-02-06
DE69623970T2 (de) 2003-06-05
US5874090A (en) 1999-02-23
CA2223643A1 (en) 1997-02-06
HUP9802252A2 (hu) 1999-01-28
EP0841928A1 (en) 1998-05-20
EP0841928B1 (en) 2002-09-25
DK0841928T3 (da) 2003-01-27
KR19990028984A (ko) 1999-04-15
AU702371B2 (en) 1999-02-18
AU6466196A (en) 1997-02-18
SK281569B6 (sk) 2001-05-10

Similar Documents

Publication Publication Date Title
GB9514451D0 (en) Sustained-release formulation
ZA955466B (en) Stereochemical wortmannin derivatives
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
NO974378D0 (no) Fremgangsmåte til behandling av gasser
ZA968957B (en) Process for the preparation of dihaloazolopyrimidines.
EP0651650A4 (en) METHOD FOR TREATING EYE DISEASES BY MEANS OF TGF - g (b).
IL121437A0 (en) Process for the preparation of nootkatone
HRP960253B1 (en) Process for the hydrogenation of imines
PH31326A (en) Methods of inhibiting breast disorders.
BG103649A (en) Method for the preparation of eprosartan
IL128028A0 (en) Treatment of psychotic disorders
ZA949563B (en) Method for treating aphthae using dimeticone.
BG103650A (en) Method for the preparation of eprosartan
PL322279A1 (en) Method of obtaining 1,2-benzoylthiazolin-3-ones
IL118200A0 (en) Process for the preparation of substituted 2-fluoro-pyrimidines
ZA96897B (en) Methods of inhibiting effects of IL-6.
IL118788A0 (en) Process for the hydrogenation of imines
EP0383937A4 (en) Process for treating by-product oil
ZA949564B (en) Method for treating constipation using dimeticone.
ZA966452B (en) Process for the preparation of substituted aminocarbonyltriazolinones.
IL122312A0 (en) Process for the hydrogenation of imines
ZA966384B (en) Process for the hydrogenation of imines
IL120556A0 (en) Process for the preparation of 3,3,5-trichloroglutarimide
IL115855A0 (en) Process for the preparation of disubstituted benzophenones
IT1283267B1 (it) "apparecchio per trattare calzature."